Cytokinetics, Inc. will not continue to pursue US FDA approval of its lead cardiac myosin activator, omecamtiv mecarbil, after receiving a complete response letter, but the company will use its opportunity for a post-CRL meeting with the agency to gain insights that could improve the drug’s chances of approval overseas.
The omecamtiv mecarbil NDA for treatment of patients with heart failure with reduced ejection fraction (HFrEF) was based on a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?